Process Analytical Technology (PAT) and Quality by Design (QbD) in the regulatory environment of the pharmaceutical industry;PAT und QbD im regulatorischen Um feld der pharmazeutischen industrie

Chemie-Ingenieur-Technik

Volumn 82, Issue 4, 2010, Pages 415-428

  Schmidt Bader, Torsten ^a  

^a MoveproTEC Life Science Advisory   (Germany)

Author keywords

GMP Regulierung; PAT QbD; Pharmazeutische industrie

Indexed keywords

EID: 77950805692     PISSN: 0009286X     EISSN: 15222640     Source Type: Journal    
DOI: 10.1002/cite.200900129     Document Type: Article

References (57)

1. U. S. Food and Drug Administration, Guidance for Industry "PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance" September", FDA, Silver Spring 2004.
2. st century - a risk-based approach, Final Report, SeptemberFDA, Silver Spring 2004.
3. Statistisches Bundesamt, http://www.destatis.de/jetspeed/portal/cms/.
4. Branchenreport Prozessfertigung: Chemie, Pharma, Lebensmittel, Microsoft Deutschland GmbH, Unterschleißheim 2009.
5. W. Klohn, Strukturen und Probleme der Bevölkerungsentwicklung, Oldenburgische Volkszeitung, Vechta 2006.
6. M. Bräuninger, T. Straubhaar, V. Fitzner, G. A. Teichmann, HWWI Policy Report Nr. 7 des HWWI-Kompetenzbereiches Wirtschaftliche Trends, Price WaterHouseCoopers, "Politik-Check Pharmastandort Deutschland: Potenziale erkennen Chancen nutzen", Hamburgisches WeltWirtschafts lnstitut, Hamburg 2008.
7. FDA Critical Path Initiative: Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products, 2004. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ ucm076689.htm.
8. Deloitte Touche Tohmatsu White Paper "The future of the life science industries: Strategies for success in 2015", DTT & The Economist Intelligence Unit, New York 2006.
9. Pharma 2020: Challenging business models, Price-WaterhouseCoopers, 2009.
10. st century, 2006 ISPE Annual Meeting und, 2006;
11. nd EMEA workshop on SMEs, 2006.
12. L. X. Yu, Pharm. Res. 2008, 25 (4), 781.
13. Food and Drug Administration CDER, Guidance for industry: Immediate release solid oral dosage forms scale-up and post-approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, FDA November, Silver Spring 1995.
14. Food and Drug Administration CDER, Guidance for industry: Modified release solid oral dosage forms scale-up and post-approval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, FDA September, Silver Spring 1997.
15. Food and Drug Administration CDER, Guidance for industry: Nonsterile semisolid dosage forms scale-up and postapproval changes: Chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, FDA May, Silver Spring 1997.
16. Food and Drug Administration CDER, Guidance for industry: Changes to an approved NDA or ANDA, FDA April, Silver Spring 2004.
17. J. Woodcock, Am. Pharm. Rev., 2004, Nov/Dec, 1-3.
18. C. Woelbeling et al, Creating QbD/PAT Management Awareness, PATCoP ISPE Affiliate D/A/CH, SPE publication, September 2007.
19. European Medicines Agency, EMEA PAT Team Position Paper, Chemical, pharmaceutical and biological information to be included in dossiers when Process Analytical Technology (PAT) is employed, EMEA/INS/277260/2005, EMEA, London 2006. http://www.emea.europa.eu/Inspections/docs/PATGuidance.pdf.
20. A. Shanley, Pharm. Manuf. 2004, 6, 41.
21. A. Hussain, PAT - the regulatory framework, Vortrag anläßlich ISPE European Congress Mai 2004, Brüssel 2004.
22. F. Erni, Chemiereport.at, Vortrag bei Innoforum, Mondsee, Februar 2008. http://www.alsa.at/chemiereport/stories/7441/
23. J. Workman, M. Koch, D. J. Veltkamp, Anal. Chem. 2003, 75 (12), 2859.
24. D. C. Hinz, Anal. Bioanal. Chem. 2006, (384), 1036.
25. ICH website, http://www.ich.org
26. ICH Harmonised Tripartite Guideline Q8 (R2), Pharmaceutical Development, step 4,Aug 2009.
27. AMG, Gesetz über den Verkehr mit Arzneimitteln vom 24.08.1976, Neufassung durch Bekanntmachung vom 12.12.2005 BGBl. I 3394, zuletzt geändert durch Art. 1 der Verordnung vom 28.09.2009 BGBl. I 3172, 3578.
28. ICH Tripartite Harmonised Guideline Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (including Decision Trees), Step, step 5, Oktober 1999.
29. FDA CDER:, Guidance for industry: Q6A specifications for new drug substances and products: Chemical substances, Silver Spring Oktober, 1999.
30. American Society for Testing and Materials, ASTM Committee E55 on manufacturing of pharmaceutical drugs, http://www.astm.org/COMMIT/COMMITTEE/E55. htm
31. FDA CDER:, Draft guidance for industry and review staff, Target product profile - A strategic development tool, Silver Spring, März 2007.
32. Product optimization, (Ed.: M. Gibson), Pharmaceutical Preformulation and formulation), Taylor & Francis, New York, 2001, 295.
33. ICH Tripartite Harmonised Guideline Q9, Quality Risk Management, step 4, November 2005.
34. ICH Tripartite Harmonised Guideline Q10, Pharmaceutical Quality System, June 2008.
35. R. Lionberger, S. L. Lee, L. M. Lee, A. Raw, L. X. Yu, Quality by Design: Concepts for ANDAs, AAPS J. 2008, (10) (2), 268.
36. F. Erni, Pharmaceutical Quality Forum, ISPE Japan, 2006.
37. A. Shanley, Risk Management Still Eludes Vaccine Manufacturers, Pharma Manufacturing, 2009.
38. EC draft variations regulations and public consultation paper version: 24. Oktober 2007. http://ec.europa.eu/enterprise/pharmaceuticals/varreg/index. htm
39. th International Pharma Forum ISPE, Yokohame, Juni 2006 und J.-L. Robert, ICH public meeting, Tokio, Japan, Juni 2009.
40. Kompetenzzentrum für Pharmceutical Engineering CCPE, Graz, http://www.pharmeng-ws2.tugraz.at/2008
41. T. Garcia, R. Nosal, G. Cook, PQLI key topics - criticality, design space, and control strategy, J. Pharm. Innov 2008, 3 (2), 60, http://www.pharmeng-ws2.tugraz.at/2008.
42. C. Potter, PQLI application of science- and risk- based approaches (ICH Q8, Q9, and Q10) to existing products, J. Pharm. Innov. 2009, 4 (1), 4.
43. R. Nosal, T. Schultz, PQLI definition and criticality, J. Pharm. Innov 2008, 3 (2), 69.
44. R. Romero, D. Gasquez, M. Sanshez, L. Rodriguez, M. Bagur, LC GC North Am. 2002, (20), 72.
45. R. S. Kenett, D. A. Kenett, Quality by Design applications in biosimilar pharmaceutical products, Accred. Qual. Assur. 2008, (13), 681.
46. Pharma 2020: Virtual R&D, Price Water house-Coopers, 2007.
47. D. P. Petrides, A. Koulouris, P. T. Lagonikos, The Role of process simulation in pharmaceutical process development and product commercialization Pharma. Eng. 2002, 22, 1.
48. K. Eichmüller, Risikomanagementim GMP-Um-feld A & R, Zeitschrift für Arzneimittel und Arzneimittelpolitik, Wissenschaftliche Verlagsgesellschaft mbH 2009, (4), 147.
49. FDA CDER, Docket Nr. FDA-2008-N-0355, Silver Spring, Juli 2008.
50. A. Mab, A Case Study in Bioprocess Development, CMC Biotech Working Group, Version 2.1, Oktober 2009, placed in the public domain by CASSS and ISPE.
51. G. Brendelberger, Quality-by-Design für Biotechnologische Produkte: neues FDA Pilot Programm, GMP News, concept Heidelberg, August 2008, http://www.gmp-navigator.com/nav-news-1253-5701,5705,5480.html
52. Verband forschender Arzneimittelunternehmen e.V. Berlin, Statistics 2009, Die Arzneimittelindustrie in Deutschland, Juli 2009, http://www.vfa.de/ download/SHOW/de/presse/publikationen/statistics-2009.pdf.
53. The Gobal Pharmaceutical Industry, http://www.duke.edu/web/soc142/team2/ trade.html.
54. Reuters, Financial Times Deutschland, 13.12.2009, http://www.ftd.de/ unternehmen/industrie/:pharmaindustrie-arzneimittelhersteller-verlieren- milliarden/50049670.html
55. B. Hughes, Nat. Rev. Drug Discovery 2008, (7), 107, http://www.nature. com/nrd/journal/v7/n2/full/nrd2514.html#t1
56. B. Hughes, Nat. Rev. Drug Discovery 2009, (8), 93, http://www.nature.com/ nrd/journal/v8/n2/full/nrd2813.html
57. B. Hughes, Nat. Rev. Drug Discovery 2010, (9), 89, http://www.nature.com/ nrd/journal/v9/n2/full/nrd3101.html